PharmaCyte Biotech, Inc. (PMCB)
2025-07-31 | 2024-10-31 | 2024-07-31 | ||
|---|---|---|---|---|
| Revenue | - | - | - | |
| Legal and professional | - | 469,685 | 510,556 | |
| Director fees | - | 138,000 | 138,000 | |
| Compensation expense | - | 283,333 | 389,484 | |
| Research and development costs | 95,157 | 97,470 | 96,016 | |
| General and administrative | 753,148 | 117,572 | 134,831 | |
| Total operating expenses | 848,305 | 1,106,060 | 1,268,887 | |
| Loss from operations | -848,305 | -1,106,060 | -1,268,887 | |
| Change in fair value of the derivative liability | - | - | 1,204,000 | |
| Other expense | -121 | -1,062 | -190 | |
| Unrealized loss on marketable securities | -104,463 | - | - | |
| Interest income | 217,793 | 382,562 | 547,432 | |
| Gain on related party investment - tnf | - | - | 21,395,734 | |
| Gain on legal settlement - re-fair value of warrants | 106,000 | - | - | |
| Change in fair value of warrant liabilities | 243,000 | 1,829,000 | 2,084,000 | |
| Change in fair value of warrants - tnf | -4,832,000 | - | - | |
| Change in fair value of warrant asset - femasys | -1,215,000 | 276,000 | -1,510,000 | |
| Change in fair value of investment - tnf | -2,839,000 | -4,265,000 | 724,266 | |
| Change in fair value of derivative liability | - | 980,000 | - | |
| Change in fair value of convertible note receivable - femasys | 912,000 | 435,000 | 245,000 | |
| Total other income (loss), net | -7,511,791 | -363,500 | 24,690,242 | |
| Net income (loss) | -8,360,096 | -1,469,560 | 23,421,355 | |
| Preferred stock dividends | - | 443,958 | 685,801 | |
| Preferred stock accretion | - | 1,045,357 | 2,148,047 | |
| Net income (loss) attributable to common stockholders | -8,360,096 | -2,958,875 | 20,587,507 | |
| Basic income (loss) per share attributable to common stockholders | -1.23 | -0.39 | 1.9 | |
| Diluted income (loss) per share attributable to common stockholders | -1.23 | -0.39 | 1.9 | |
| Weighted average shares outstanding basic | 6,795,779 | 7,637,034 | 7,866,387 | |
| Weighted average shares outstanding diluted | 6,795,779 | 7,637,034 | 7,866,387 | |